PET Scan with VAT
Phase 3Small molecule
PET Scan with VAT is one of 29 small molecule programs targeting Major Depressive Disorder (MDD). It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Imaging
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Nicorette
PfizerApproved
Obicetrapib
NNewAmsterdam Pharma
Phase 3
F-Arag
CCellSight Technologies, Inc.
Phase 2
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Phase 2
PET Scan with VAT
SStony Brook University
Phase 3
XTR006
SSinotau Pharmaceutical Group
Phase 3
Ga-FAPI-46
UUniversität Münster
Phase 2
Ethanol
RochePreclinical
Methylreboxetine
BBrigham and Women's Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PET Scan with VAT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SStony Brook University